SCHEMBL41891

SCHEMBL41891

[CH2]OC(=O)C(C)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7861990 1.00
SCHEMBL3338433 0.78
SCHEMBL5956535 0.78
SCHEMBL22685410 0.78
SCHEMBL6536106 0.75 SLC7A5 (0.36)
SCHEMBL298986 0.75
SCHEMBL2027762 0.75 SLC7A5 (0.36)
SCHEMBL17222464 0.75 SLC7A5 (0.36)
SCHEMBL866414 0.75 SLC7A5 (0.36)
SCHEMBL709252 0.75 SLC7A5 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 530 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131032-A1 NEUROTHERAPEUTIC TREATMENT FOR SEXUAL DYSFUNCTION REVAAX PHARMACEUTICALS, LLC (US) 2013-05-23 US claimed
US-7355040-B2 Process for the preparation of cephalosporin compounds and synthetic intermediates ZOETIS SERVICES LLC 2008-04-08 US claimed
EP-0725783-B1 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES SMITHKLINE BEECHAM PLC (GB) 2002-12-18 EP claimed
EP-0915843-A1 AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSES SMITHKLINE BEECHAM PLC (GB) 1999-05-19 EP claimed
WO-1997041098-A1 AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1997-11-06 WO claimed
EP-0148883-B1 ALLOPURINOL PRODRUGS A/S GEA Farmaceutisk Fabrik (DK) 1990-02-14 EP claimed
US-20240115553-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY AZEVAN PHARMACEUTICALS, INC. (US) 2024-04-11 US disclosed
WO-2024064209-A1 COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS DATA2DISCOVERY, INC. (US) 2024-03-28 WO disclosed
US-20230123729-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AZEVAN PHARMACEUTICALS INC (US) 2023-04-20 US disclosed
US-11628160-B2 Compositions and methods for treating brain injury AZEVAN PHARMACEUTICALS, INC. (US) 2023-04-18 US disclosed
US-11319306-B2 Compositions and methods for treating neurodegenerative diseases AZEVAN PHARMACEUTICALS, INC. (US) 2022-05-03 US disclosed
US-11160770-B2 Compounds, compositions and methods for treating oxidative DNA damage disorders INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2021-11-02 US disclosed
US-20210290787-A1 MACROCYCLE CONJUGATES LUMIPHORE, INC. 2021-09-23 US disclosed
US-4694006-A Acyl- or acyloxymethyl-allopurinol prodrugs A/S GEA (DK) 1987-09-15 US disclosed
EP-0219926-A2 Cephalosporins, processes for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1987-04-29 EP disclosed
EP-0211656-A2 Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1987-02-25 EP disclosed
EP-0210815-A2 6-Beta-(alpha-etherified oxyimino)-acylamino penicillanic-acid derivatives, their preparation and use BEECHAM GROUP PLC (GB) 1987-02-04 EP disclosed
EP-0148883-A1 ALLOPURINOL PRODRUGS. GEA AS (DK) 1985-07-24 EP disclosed
WO-1985000368-A1 ALLOPURINOL PRODRUGS A/S GEA (DK) 1985-01-31 WO disclosed
US-3965099-A Cephalosporin esters with antibacterial activity SMITHKLINE CORPORATION (US) 1976-06-22 US disclosed